Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...

Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated ...

NEW YORK (PIX11) — A young man, homeless and disheveled, was surrounded by a joint response team made up of two NYPD officers ...

T cell engagers are having a moment, much like antibody-drug conjugates have for the past two years. The cell-depleting ...

Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated ...

GSK has claimed its second breakthrough designation ... extensive-stage SCLC. Ouro launches today with $120m in funding and a plan to develop bispecific antibody-based T cell engagers for ...

(Bloomberg) -- When Elliott Investment Management came calling for the ouster of Emma Walmsley, the chief executive officer ...

GSK and Pfizer’s full-year financial results show that the former is currently winning the battle for take-up of their rival respiratory syncytial virus (RSV) vaccines, although, there are signs ...

GSK plc's stock downgraded from “Buy” to “Hold” due to litigation risks, disappointing RSV vaccine sales, and competitive pressures in the HIV space. Despite strong cash flow, GSK's Zantac ...

Partnership is integral to GSK. Bringing people together is the best way to innovate and deliver products that transform the standard of care and improve lives. Over half of GSK’s clinical ...

GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 ...